A Phase 1b Study Evaluating the Safety and Efficacy of IBI188 in Combination With Azacitidine in Subjects With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (MDS)
Latest Information Update: 22 Dec 2020
At a glance
- Drugs Azacitidine (Primary) ; Letaplimab (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Innovent Biologics
- 13 Dec 2020 Status changed from recruiting to suspended (Clinical hold).
- 27 Aug 2020 Planned primary completion date changed from 31 Mar 2021 to 31 Oct 2021.
- 27 Aug 2020 Status changed from not yet recruiting to recruiting.